Navigation Links
Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe
Date:10/7/2008

ANTONY, France, October 7 /PRNewswire-FirstCall/ -- Stallergenes S.A. today announced that they have entered into an exclusive agreement with Catalent for the promotion and distribution in Europe of adrenaline autoinjector, ADREFLEX(R), co-developed and co-manufactured by Catalent and The Medical House PLC.

ADREFLEX(R) consists of a syringe pre-filled with adrenaline, which will be available for adult and paediatric use (0.3 and 0.15 mg), in an autoinjector device. The Medical House has designed this totally new device to improve the safety and the ease-of-use for patients.

The adrenaline autoinjector is designed for the emergency treatment of anaphylactic shock, mostly due to hymenoptera venom or food allergies, and for use by the patient himself or a relative in the event of an emergency.

Catalent expects to submit the file of ADREFLEX(R) dossier for registration in Europe in 2009. Upon approval, Stallergenes will then promote and distribute the product on an exclusive basis in 13 European countries, including the five main markets (UK, France, Germany, Italy, and Spain).

"This agreement with Catalent and The Medical House fits in perfectly with our product portfolio offered to allergy specialists and with our philosophy regarding state-of-the-art in-licensed complementary products," said Albert Saporta, Chairman and CEO of Stallergenes. "We expect the European market to double in size in the coming years. Furthermore, this agreement represents a unique opportunity for Stallergenes to set up its own commercial operation in the United Kingdom in the near future. This market accounts for 50% of the adrenaline European market."

The terms of the agreement are undisclosed.

About anaphylactic shock

Anaphylactic shock is a severe life threatening reaction that can affect all age groups, leading to urticaria and angioedema, bronchoconstriction and hypotension. Mediator release results in smooth muscle contraction, vasodilatation, increased vascular permeability.

Intramuscular adrenaline is a vasoconstrictor, the first line treatment for anaphylactic shock, for patient self administration. Any patient with a severe systemic allergic reaction should be considered for adrenaline autoinjector.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% in raw data of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2007, Stallergenes realised sales of EUR 147 million, mainly achieved in the European markets.

Stallergenes is listed on Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP

Additional information on Stallergenes is available at: http://www.stallergenes.com

About The Medical House PLC

The Medical House PLC (TMH) is a group of companies which specialises in the design, development, licensing and supply of innovative medical devices for global pharmaceutical and biotechnology industry clients.

TMH's activities are primarily focused on drug delivery technologies (through Medical House Products Ltd). These activities are supported by in-house design and rapid prototyping capabilities.

Founded in 1998, TMH was admitted to London Stock Exchange's Alternative Investment Market (A.I.M.) in 2000.

For more information, visit http://www.themedicalhouse.com.


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
5. AtriCure to Present at Roth Capital Partners 2007 New York Conference
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. National Patient Safety Foundation Partners with Vocera Communications
11. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: